ABSTRACT
Hemostasis is traditionally defined as the physiologic process whereby bleeding is
antagonized and possibly stopped to minimize blood loss. The first medical description
of the clinical and inherited features of hemostasis can be dated back more than 1000
years, when Abu al-Qasim Khalaf ibn ‘Abbas al-Andalusi al-Zahrawi’ medical treatise
provided some initial insights into this puzzling process. Since then, continuous
and revolutionary scientific developments have contributed to decoding several aspects
of this intricate but essential physiologic phenomenon, providing a reliable model
to explain the leading mechanisms involved. Although the point at which bleeding stops
is commonly referred to as “coagulation,” blood coagulation is actually only one part
of a two-part hemostatic process that develops through sequential steps referred to
as primary and secondary hemostasis. Throughout its activation and development, the
coagulation cascade is strictly regulated by a series of natural inhibitors, which
prevent unnecessary and excessive clotting. The aim of this article is to provide
a concise overview of the major discoveries and past and current perspectives in coagulation
and hemostasis.
KEYWORDS
Coagulation - hemorrhage - hemostasis - history - thrombosis
REFERENCES
1 al-Qasim Khalaf A, al-Andalusi al-Zahraw A. Medical treatise Kitab al-tasrîf liman ajaza an al-talîf fi al-tibb
. Available at: http://www.museumwnf.net/database_item.php?id=object;ISL;ma;Mus01_F;16;en Accessed February 27, 2009
2
Schultze M.
Ein heizbarer Objecttisch und seine Verwendung bei Untersuchungen des Blutes.
Arch Mikrosc Anat.
1865;
1
1-42
3
Bizzozero J.
Über einen neuen Forrnbestandteil des Blutes und dessen Rolle bei der Thrombose und
Blutgerinnung.
Arch Pathol Anat Physiol Klin Med.
1882;
90
261-332
4
Brewer D B.
Max Schultze (1865), G. Bizzozero (1882) and the discovery of the platelet.
Br J Haematol.
2006;
133
251-258
5
Hayward C P, Eikelboom J.
Platelet function testing: quality assurance.
Semin Thromb Hemost.
2007;
33
273-282
6
Briggs C, Harrison P, Machin S J.
Continuing developments with the automated platelet count.
Int J Lab Hematol.
2007;
29
77-91
7
Singh H, Chaudhary R, Ray V.
Platelet indices as quality markers of platelet concentrates during storage.
Clin Lab Haematol.
2003;
25
307-310
8
Abe Y, Wada H, Sakakura M et al..
Usefulness of fully automated measurement of reticulated platelets using whole blood.
Clin Appl Thromb Hemost.
2005;
11
263-270
9
Althaus K, Greinacher A.
MYH9-related platelet disorders.
Semin Thromb Hemost.
2009;
, in press
10
The British Society for Haematology BCSH Haemostasis and Thrombosis Task Force .
Guidelines on platelet function testing.
J Clin Pathol.
1988;
41
1322-1330
11
Ivy A C, Nelson D, Buchet C.
The standardization of certain factors in the cutaneous “venostasis” bleeding time
technique.
J Lab Clin Med.
1941;
26
1812-1941
12
Favaloro E J, Smith J, Petinos P, Collecutt M, Street A, Hertzberg M. on behalf of
the RCPA Quality Assurance Program (QAP) in Haematology Scientific Haemostasis Advisory
Panel .
Laboratory testing, diagnosis and management of von Willebrand's disease: current
practice in Australasia.
Am J Clin Pathol.
1999;
112
712-719
13
Fressinaud E, Veyradier A, Truchaud F et al..
Screening for von Willebrand disease with a new analyser using high shear stress:
a study of 60 cases.
Blood.
1998;
91
1325-1331
14
Lind S E.
The bleeding time does not predict surgical bleeding.
Blood.
1991;
77
2547-2552
15
De Caterina R, Lanza M, Manca G, Strata G B, Maffei S, Salvatore L.
Bleeding time and bleeding: an analysis of the relationship of the bleeding time test
with parameters of surgical bleeding.
Blood.
1994;
84
3363-3370
16
Born G V.
Aggregation of blood platelets by adenosine diphosphate and its reversal.
Nature.
1962;
194
927-929
17
McGlasson D, Fritsma G A.
Whole blood aggregometry.
Semin Thromb Hemost.
2009;
, in press
18
Cattaneo M.
Light transmission aggregometry and ATP release for the diagnostic assessment of platelet
function.
Semin Thromb Hemost.
2009;
, in press
19
Cardigan R, Turner C, Harrison P.
Current methods of assessing platelet function: relevance to transfusion medicine.
Vox Sang.
2005;
88
153-163
20
Favaloro E J.
Internal quality control and external quality assesment of platelet function tests.
Semin Thromb Hemost.
2009;
, in press
21
Hartert H.
Blutgerinnungsstudien mit der Thrombeastographie, einem neuen Untersuchungsverfahren.
Klin Wochenschr.
1948;
26
577-583
22
Luddington R J.
Thrombelastography/thromboelastometry.
Clin Lab Haematol.
2005;
27
81-90
23
Adams M, Ward C, Thom J et al..
Emerging technologies in hemostasis diagnostics: a report from the Australasian Society
of Thrombosis and Haemostasis Emerging Technologies Group.
Semin Thromb Hemost.
2007;
33
226-234
24
Watson H G, Greaves M.
Can we predict bleeding?.
Semin Thromb Hemost.
2008;
34
97-103
25
Dempfle C E, Borggrefe M.
Point of care coagulation tests in critically ill patients.
Semin Thromb Hemost.
2008;
34
445-450
26
Baumgartner H R.
The role of blood flow in platelet adhesion, fibrin deposition, and formation of mural
thrombi.
Microvasc Res.
1973;
5
167-179
27
Kratzer M A, Born G V.
Simulation of primary haemostasis in vitro.
Haemostasis.
1985;
15
357-362
28
Favaloro E J.
Clinical utility of the PFA-100.
Semin Thromb Hemost.
2008;
34
709-733
29
Smith J W, Steinhubl S R, Lincoff A M et al..
Rapid platelet-function assay. An automated and quantitative cartridge-based method.
Circulation.
1999;
99
620-625
30 Varon D, Savion N.
Cone and platelet analyzer . In Michelson AD Platelets. London, UK; Academic Press 2002: 337-345
31
Harrison P, Mumford A.
Screening tests of platelet function – update on their appropriate uses for diagnostic
testing.
Semin Thromb Hemost.
2009;
, in press
32
Rinder H M.
Platelet function testing by flow cytometry.
Clin Lab Sci.
1998;
11
365-372
33
Enjeti A K, Lincz L F, Seldon M.
Detection and measurement of microparticles: an evolving research tool for vascular
biology.
Semin Thromb Hemost.
2007;
33
771-779
34
Liu J, DeNofrio J, Yuan W, Wang Z, McFadden A W, Parise L V.
Genetic manipulation of megakaryocytes to study platelet function.
Curr Top Dev Biol.
2008;
80
311-335
35
Senzel L, Gnatenko D V, Bahou W F.
Genomic and proteomic applications in diagnosis of platelet disorders and classification.
Semin Thromb Hemost.
2008;
34
532-538
36
Franchini M, Lippi G.
The role of von Willebrand factor in hemorrhagic and thrombotic disorders.
Crit Rev Clin Lab Sci.
2007;
44
115-149
37
von Willebrand E A.
Hereditar pseudohemofili.
Finska Lak-Sallsk Handl.
1926;
67
87-112
38
Nilsson I M, Blomback M, Jorpes E.
Von Villebrand's disease and its correction with human plasma fraction 1–0.
Acta Med Scand.
1957;
159
179-188
39 Zimmerman T S, Ruggeri Z M. Coagulation and Bleeding Disorders: The Role of Factor
VIII and von Willebrand Factor. New York, NY; Marcel Dekker 1989
40
Owen W G, Wagner R H.
Antihemophilic factor: separation of an active fragment following dissociation by
salts or detergents.
Thromb Diath Haemorrh.
1972;
27
502-515
41
Ginsburg D, Handin R I, Bonthron D T et al..
Human von Willebrand factor (vWF): isolation of complementary DNA (cDNA) clones and
chromosomal localization.
Science.
1985;
228
1401-1406
42
Lynch D C, Zimmerman T S, Collins C J et al..
Molecular cloning of cDNA for human von Willebrand factor: authentication by a new
method.
Cell.
1985;
41
49-56
43
Sadler J E, Shelton-Inloes B B, Sorace J M, Harlan J M, Titani K, Davie E W.
Cloning and characterization of two cDNAs coding for human von Willebrand factor.
Proc Natl Acad Sci U S A.
1985;
82
6394-6398
44
Federici A B, Castaman G, Mannucci P M. Italian Association of Hemophilia Centers
(AICE) .
Guidelines for the diagnosis and management of von Willebrand disease in Italy.
Haemophilia.
2002;
8
607-621
45
Favaloro E J.
Laboratory identification of von Willebrand disease: technical and scientific perspectives.
Semin Thromb Hemost.
2006;
32
456-471
46
Favaloro E J.
An update on the von Willebrand factor collagen binding (VWF:CB) assay: 21 years of
age and beyond adolescence, but not yet a mature adult.
Semin Thromb Hemost.
2007;
33
727-744
47
Howard M A, Firkin B G.
Ristocetin - a new tool in the investigation of platelet aggregation.
Thromb Diath Haemorrh.
1971;
26
362-369
48
Weiss H J, Hoyer L W, Rickles F R, Varma A, Rogers J.
Quantitative assay of a plasma factor deficient in von Willebrand's disease that is
necessary for platelet aggregation. Relationship to factor VIII procoagulant activity
and antigen content.
J Clin Invest.
1973;
52
2708-2716
49
Favaloro E J, Bonar R, Marsden K.
(on behalf of the RCPA QAP Haemostasis Committee). Lower limit of assay sensitivity:
an under-recognised and significant problem in von Willebrand disease identification
and classification.
Clin Lab Sci.
2008;
21
178-185
50
Favaloro E J, Bonar R, Meiring M, Street A, Marsden K.
(on behalf of the RCPA QAP in Haematology). 2B or not 2B? Disparate discrimination
of functional VWF discordance using different assay panels or methodologies may lead
to success or failure in the early identification of type 2B VWD.
Thromb Haemost.
2007;
98
346-358
51
Kempfer A C, Silaf M R, Farias C E et al..
Binding of von Willebrand factor to collagen by flow cytometry.
Am J Clin Pathol.
1999;
111
418-423
52
Chen D, Daigh C A, Hendricksen J I et al..
A highly sensitive plasma von Willebrand factor ristocetin cofactor (VWF:RCo) activity
assay by flow cytometry.
J Thromb Haemost.
2008;
6
323-330
53
Giannini S, Mezzasoma A M, Leone M, Gresele P.
Laboratory diagnosis and monitoring of desmopressin treatment of von Willebrand's
disease by flow cytometry.
Haematologica.
2007;
92
1647-1654
54
Blombäck B.
Fibrinogen: evolution of the structure-function concept. Keynote address at Fibrinogen
2000 Congress.
Ann N Y Acad Sci.
2001;
936
1-10
55
Schmidt A.
Neue Untersuchungen ueber die Fasserstoffesgerinnung.
Pflueger's Arch F Ges Physiol.
1872;
6
413-538
56
Monroe D M, Hoffman M, Roberts H R.
Fathers of modern coagulation.
Thromb Haemost.
2007;
98
3-5
57
MacFarlane R G.
An enzyme cascade in the blood clotting mechanism and its function as a biochemical
amplifier.
Nature.
1964;
202
498-499
58
Davie E W, Ratnoff O D.
Waterfall sequence for intrinsic blood clotting.
Science.
1964;
145
1310-1312
59
Mann K G.
Biochemistry and physiology of blood coagulation.
Thromb Haemost.
1999;
82
165-174
60
Hemker H C.
The initiation phase - a review of old (clotting-) times.
Thromb Haemost.
2007;
98
20-23
61
Lippi G, Franchini M, Guidi G C.
Diagnostic approach to inherited bleeding disorders.
Clin Chem Lab Med.
2007;
45
2-12
62
McVey J H.
Tissue factor pathway.
Baillieres Best Pract Res Clin Haematol.
1999;
12
361-372
63
Mackman N, Tilley R E, Key N S.
Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis.
Arterioscler Thromb Vasc Biol.
2007;
27
1687-1693
64
Koller F, Loeliger A, Duckert F.
Experiments on a new clotting factor (factor VII).
Acta Haematol.
1951;
6
1-18
65
Eigenbrot C.
Structure, function, and activation of coagulation factor VII.
Curr Protein Pept Sci.
2002;
3
287-299
66
Franchini M, Veneri D, Lippi G.
The potential role of recombinant activated FVII in the management of critical hemato-oncological
bleeding: a systematic review.
Bone Marrow Transplant.
2007;
39
729-735
67
Kato H.
Regulation of functions of vascular wall cells by tissue factor pathway inhibitor:
basic and clinical aspects.
Arterioscler Thromb Vasc Biol.
2002;
22
539-548
68
Römisch J.
Factor VII activating protease (FSAP): a novel protease in hemostasis.
Biol Chem.
2002;
383
1119-1124
69
Lisman T, De Groot P G.
Mechanism of action of recombinant factor VIIa.
J Thromb Haemost.
2003;
1
1138-1139
70
Middeldorp S, Levi M.
Thrombophilia: an update.
Semin Thromb Hemost.
2007;
33
563-572
71
Mahmoodi B K, Brouwer J L, Veeger N J, van der Meer J.
Hereditary deficiency of protein C or protein S confers increased risk of arterial
thromboembolic events at a young age. Results from a large family cohort study.
Circulation.
2008;
118
1659-1667
72
Prandoni P, Bilora F, Marchiori A et al..
An association between atherosclerosis and venous thrombosis.
N Engl J Med.
2003;
348
1435-1441
73
Boekholdt S M, Kramer M H.
Arterial thrombosis and the role of thrombophilia.
Semin Thromb Hemost.
2007;
33
588-596
74
Sorensen H T, Horvath-Puho E, Pedersen L, Baron J A, Prandoni P.
Venous thromboembolism and subsequent hospitalisation due to acute arterial cardiovascular
events: a 20-year cohort study.
Lancet.
2007;
370
1773-1779
75
Ageno W, Becattini C, Brighton T, Selby R, Kamphuisen P W.
Cardiovascular risk factors and venous thromboembolism: a meta-analysis.
Circulation.
2008;
117
93-102
76
Egeberg O.
Inherited antithrombin deficiency causing thrombophilia.
Thromb Diath Haemorrh.
1965;
13
516-530
77
Nicolaides A N, Breddin H K, Carpenter P The European Genetics Foundation et al..
Thrombophilia and venous thromboembolism. International consensus statement. Guidelines
according to scientific evidence.
Int Angiol.
2005;
24
1-26
78
van Boven H H, Vandenbroucke J P, Briët E, Rosendaal F R.
Gene-gene and gene-environment interactions determine risk of thrombosis in families
with inherited antithrombin deficiency.
Blood.
1999;
94
2590-2594
79
Cohn D M, Roshani S, Middeldorp S.
Thrombophilia and venous thromboembolism: implications for testing.
Semin Thromb Hemost.
2007;
33
573-581
80
Marcum J A.
The origin of the dispute over the discovery of heparin.
J Hist Med Allied Sci.
2000;
55
37-66
81
Fareed J, Hoppensteadt D A, Fareed D et al..
Survival of heparins, oral anticoagulants, and aspirin after the year 2010.
Semin Thromb Hemost.
2008;
34
58-73
82
Howell W H, Holt E.
Two new factors in blood coagulation – heparin and pro-antithrombin.
Am J Physiol.
1918;
47
328-341
83
Wardrop D, Keeling D.
The story of the discovery of heparin and warfarin.
Br J Haematol.
2008;
141
757-763
84
Fareed J, Leong W L, Hoppensteadt D A et al..
Generic low-molecular-weight heparins: some practical considerations.
Semin Thromb Hemost.
2004;
30
703-713
85
Spinler S A, Wittkowsky A K, Nutescu E A, Smythe M A.
Anticoagulation monitoring part 2: unfractionated heparin and low-molecular-weight
heparin.
Ann Pharmacother.
2005;
39
1275-1285
86
Bianchini P, Liverani L, Spelta F, Mascellani G, Parma B.
Variability of heparins and heterogeneity of low molecular weight heparins.
Semin Thromb Hemost.
2007;
33
496-502
87
Esmon C T.
The protein C pathway.
Chest.
2003;
124(3, Suppl)
26S-32S
88
Griffin J H, Evatt B, Zimmerman T S, Kleiss A J, Wideman C.
Deficiency of protein C in congenital thrombotic disease.
J Clin Invest.
1981;
68
1370-1373
89
Nizzi Jr F A, Kaplan H S.
Protein C and S deficiency.
Semin Thromb Hemost.
1999;
25
265-272
90
Martí-Carvajal A, Salanti G, Cardona A F.
Human recombinant activated protein C for severe sepsis.
Cochrane Database Syst Rev.
2008;
(1)
CD004388
91
Di Scipio R G, Hermodson M A, Yates S G, Davie E W.
A comparison of human prothrombin, factor IX (Christmas factor), factor X (Stuart
factor), and protein S.
Biochemistry.
1977;
16
698-706
92
Walker F J.
Regulation of activated protein C by a new protein. A possible function for bovine
protein S.
J Biol Chem.
1980;
255
5521-5524
93
García de Frutos P, Fuentes-Prior P, Hurtado B, Sala N.
Molecular basis of protein S deficiency.
Thromb Haemost.
2007;
98
543-556
94
Comp P C, Esmon C.
Recurrent venous thromboembolism in patients with a partial deficiency of protein
S.
N Engl J Med.
1984;
311
1525-1528
95
Goodwin A J, Rosendaal F R, Kottke-Marchant K, Bovill E G.
A review of the technical, diagnostic, and epidemiologic considerations for protein
S assays.
Arch Pathol Lab Med.
2002;
126
1349-1366
96
Bertina R M, Koeleman B P, Koster T et al..
Mutation in blood coagulation factor V associated with resistance to activated protein
C.
Nature.
1994;
369
64-67
97
Dahlbäck B, Carlsson M, Svensson P J.
Familial thrombophilia due to a previously unrecognized mechanism characterized by
poor anticoagulant response to activated protein C: prediction of a cofactor to activated
protein C.
Proc Natl Acad Sci U S A.
1993;
90
1004-1008
98
Koster T, Rosendaal F R, de Ronde H, Briët E, Vandenbroucke J P, Bertina R M.
Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden
Thrombophilia Study.
Lancet.
1993;
342
1503-1506
99
Svensson P J, Dahlbäck B.
Resistance to activated protein C as a basis for venous thrombosis.
N Engl J Med.
1994;
330
517-522
100
Bauduer F, Lacombe D, Factor V.
Leiden, prothrombin 20210A, methylenetetrahydrofolate reductase 677T, and population
genetics.
Mol Genet Metab.
2005;
86
91-99
101
Rosendorff A, Dorfman D M.
Activated protein C resistance and factor V Leiden: a review.
Arch Pathol Lab Med.
2007;
131
866-871
102
Norstrøm E, Thorelli E, Dahlbäck B.
Functional characterization of recombinant FV Hong Kong and FV Cambridge.
Blood.
2002;
100
524-530
103
Steen M, Norstrom E A, Tholander A L et al..
Functional characterization of factor V–Ile359Thr: a novel mutation associated with
thrombosis.
Blood.
2004;
103
3381-3387
104
Lunghi B, Iacoviello L, Gemmati D et al..
Detection of new polymorphic markers in the factor V gene: association with factor
V levels in plasma.
Thromb Haemost.
1996;
75
45-48
105
Castaman G, Faioni E M, Tosetto A, Bernardi F.
The factor V HR2 haplotype and the risk of venous thrombosis: a meta-analysis.
Haematologica.
2003;
88
1182-1189
106
Tormene D, Fortuna S, Tognin G et al..
The incidence of venous thromboembolism in carriers of antithrombin, protein C or
protein S deficiency associated with the HR2 haplotype of factor V: a family cohort
study.
J Thromb Haemost.
2005;
3
1414-1420
107
Varga E A, Kerlin B A, Wurster M W.
Social and ethical controversies in thrombophilia testing and update on genetic risk
factors for venous thromboembolism.
Semin Thromb Hemost.
2008;
34
549-561
108
Hertzberg M, Neville S, Favaloro E J, MacDonald D.
External quality assurance of DNA testing for thrombophilia mutations.
Am J Clin Pathol.
2005;
123
189-193
109
Favaloro E J.
Diagnostic issues in thrombophilia: a laboratory scientist's view.
Semin Thromb Hemost.
2005;
31
11-16
110
Favaloro E J, Bonar R, Sioufi J on behalf of the RCPA QAP in Haematology et al.
Multi-laboratory testing of thrombophilia: current and past practice in Australasia
as assessed through the Royal College of Pathologists of Australasia Quality Assurance
Program in Haematology.
Semin Thromb Hemost.
2005;
31
49-58
111
Reitsma P H, Rosendaal F R.
Past and future of genetic research in thrombosis.
J Thromb Haemost.
2007;
5(Suppl 1)
264-269
112
Bernardi E, Pesavento R, Prandoni P.
Upper extremity deep venous thrombosis.
Semin Thromb Hemost.
2006;
32
729-736
Prof. Giuseppe LippiM.D.
Sezione di Chimica Clinica, Dipartimento di Scienze Morfologico-Biomediche, Università
degli Studi di Verona
Ospedale Policlinico G.B. Rossi, Piazzale Scuro, 10 37134 Verona, Italy
Email: giuseppe.lippi@univr.it